A randomized, placebo-controlled, double-blinded Phase III trial of XmAb5871 in IgG4-RD
Phase of Trial: Phase III
Latest Information Update: 27 Feb 2018
At a glance
- Drugs XmAb 5871 (Primary)
- Indications Immunological disorders
- Focus Therapeutic Use
- 27 Feb 2018 According to a Xencor media release, Engagement with the European Medicines Agency to discuss a path forward for Phase 3 development in IgG4-RD expected in early 2018.
- 14 Nov 2017 New trial record
- 07 Nov 2017 According to a Xencor media release, the company met with the Division of Pulmonary, Allergy and Respiratory Products (DPARP) of FDA to discuss this trial.